Regenxbio (NASDAQ: RGNX) reported Q1 EPS of ($1.53), $0.15 worse than the analyst estimate of ($1.38). Revenue for the quarter came in at $19.14 million versus the consensus estimate of $31.97 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.